This case demonstrates xeligekimab—a novel fully humanized anti-IL-17A IgG4 monoclonal antibody (China-approved, August 2024)—effectively managing concurrent psoriasis, hidradenitis suppurativa, hepatitis B, and metastatic colorectal cancer, providing clinical validation for this paradigm shift. Here, IL17A is linked to hidradenitis suppurativa.